UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 134

Sortiert nach

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

Journal of hematology and oncology, 2017-03, Vol.10 (1), p.73-73, Article 73

2017

Volltextzugriff (PDF)

Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells results in EWS/FLI-1-dependent, ewing sarcoma-like tumors

Cancer research (Chicago, Ill.), 2005-10, Vol.65 (19), p.8698-8705

2005

Volltextzugriff (PDF)

Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer

Clinical pharmacokinetics, 2018-03, Vol.57 (3), p.355-365

2018

Volltextzugriff (PDF)

STAT5 signaling is required for the efficient induction and maintenance of CML in mice

Blood, 2006-06, Vol.107 (12), p.4917-4925

2006

Volltextzugriff (PDF)

Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma

Cancer chemotherapy and pharmacology, 2019-01, Vol.83 (1), p.191-199

2019

Volltextzugriff (PDF)

The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia

Blood, 2003-06, Vol.101 (12), p.5010-5013

2003

Volltextzugriff (PDF)

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia

Blood, 2005-05, Vol.105 (10), p.3995-4003

2005

Volltextzugriff (PDF)

Imatinib Mesylate Efficiently Achieves Therapeutic Intratumor Concentrations in Vivo but Has Limited Activity in a Xenograft Model of Small Cell Lung Cancer

Clinical cancer research, 2004-05, Vol.10 (10), p.3528-3534

2004

Volltextzugriff (PDF)

Imatinib Mesylate Inhibits Antigen-Specific Memory CD8 T Cell Responses In Vivo

Journal of Immunology, 2007-02, Vol.178 (4), p.2028-2037

2007

Volltextzugriff (PDF)

Pathobiology of lymphoid and myeloid blast crisis and management issues

Hematology, 2005, Vol.2005 (1), p.188-194

Ilaria, Jr, Robert L

2005

Volltextzugriff (PDF)

Regulation of Microtubule Dynamics and Myogenic Differentiation by MURF, a Striated Muscle RING-Finger Protein

The Journal of cell biology, 2000-08, Vol.150 (4), p.771-784

2000

Volltextzugriff (PDF)

Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571

Blood, 2001-11, Vol.98 (9), p.2808-2816

2001

Volltextzugriff (PDF)

A phase 2 study of tasisulam sodium (LY573636 sodium) as second‐line treatment for patients with unresectable or metastatic melanoma

Cancer, 2011-10, Vol.117 (20), p.4732-4739

2011

Volltextzugriff (PDF)

Alteration of Mesodermal Cell Differentiation by EWS/FLI-1, the Oncogene Implicated in Ewing's Sarcoma

Molecular and Cellular Biology, 2003-01, Vol.23 (2), p.482-492

2003

Volltextzugriff (PDF)

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

Cancer chemotherapy and pharmacology, 2011-11, Vol.68 (5), p.1233-1241

2011

Volltextzugriff (PDF)

The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity

The Journal of experimental medicine, 1999-05, Vol.189 (9), p.1399-1412

1999

Volltextzugriff (PDF)

P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members

The Journal of biological chemistry, 1996-12, Vol.271 (49), p.31704-31710

1996

Volltextzugriff (PDF)

AML: Many new tools for discovery, not enough answers (yet)

Leukemia research, 2006-09, Vol.30 (9), p.1073-1075

Ilaria, Robert L.

2006

Volltextzugriff (PDF)

Animal models of chronic myelogenous leukemia

Hematology/oncology clinics of North America, 2004-06, Vol.18 (3), p.525-543

Ilaria, Robert L

2004

Volltextzugriff (PDF)

Bcr/Abl, leukemogenesis, and genomic instability: a complex partnership

Leukemia research, 2002-11, Vol.26 (11), p.971-973

Ilaria, Robert L

2002

Volltextzugriff (PDF)

Tyrosine kinases in AML: where do they fit in?

Leukemia research, 2004-03, Vol.28 (3), p.217-218

Ilaria, Robert L

2004

Volltextzugriff (PDF)

The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia–like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase

Blood, 2001-01, Vol.97 (1), p.4-13

2001

Volltextzugriff (PDF)

The epidermal growth factor receptor HER2 is not a major therapeutic target in Ewing sarcoma

Journal of pediatric hematology/oncology, 2003-06, Vol.25 (6), p.459-466

2003

Volltextzugriff (PDF)

STAT isoforms: mediators of STAT specificity or leukemogenesis?

Leukemia research, 2001-06, Vol.25 (6), p.483-484

Ilaria, Robert L

2001

Volltextzugriff (PDF)

A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.10501-10501

2015

Volltextzugriff (PDF)

1 – 25 von 134

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(127)
Mit Volltextzugriff
(114)

Publikationsform

Artikel
(129)
Buchkapitel
(2)
Bücher
(2)
Texte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(12)
Nature
(6)
Leukemia Research
(5)
Nature Genetics
(5)
Human Molecular Genetics
(3)
Journal Of Clinical Oncology
(3)
Cancer Chemotherapy And Pharmacology
(2)
Cancer Research
(2)
Circulation
(2)
Frontiers In Physiology
(2)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells results in EWS/FLI-1-dependent, ewing sarcoma-like tumors

Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer

STAT5 signaling is required for the efficient induction and maintenance of CML in mice

Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma

The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia

Imatinib Mesylate Efficiently Achieves Therapeutic Intratumor Concentrations in Vivo but Has Limited Activity in a Xenograft Model of Small Cell Lung Cancer

Imatinib Mesylate Inhibits Antigen-Specific Memory CD8 T Cell Responses In Vivo

Pathobiology of lymphoid and myeloid blast crisis and management issues

Regulation of Microtubule Dynamics and Myogenic Differentiation by MURF, a Striated Muscle RING-Finger Protein

Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571

A phase 2 study of tasisulam sodium (LY573636 sodium) as second‐line treatment for patients with unresectable or metastatic melanoma

Alteration of Mesodermal Cell Differentiation by EWS/FLI-1, the Oncogene Implicated in Ewing's Sarcoma

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity

P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members

AML: Many new tools for discovery, not enough answers (yet)

Animal models of chronic myelogenous leukemia

Bcr/Abl, leukemogenesis, and genomic instability: a complex partnership

Tyrosine kinases in AML: where do they fit in?

The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia–like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase

The epidermal growth factor receptor HER2 is not a major therapeutic target in Ewing sarcoma

STAT isoforms: mediators of STAT specificity or leukemogenesis?

A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS)

Suchergebnisse filtern